These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 12760190)

  • 21. Antithrombotic treatment in atrial fibrillation.
    Kalra L; Lip GY;
    Heart; 2007 Jan; 93(1):39-44. PubMed ID: 16952971
    [No Abstract]   [Full Text] [Related]  

  • 22. Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for non-adherence and moving forwards with simplifying risk stratification for stroke and bleeding.
    Fauchier L; Lip GY
    Europace; 2010 Jun; 12(6):761-3. PubMed ID: 20388635
    [No Abstract]   [Full Text] [Related]  

  • 23. Stratification with CHA2DS2-VASc score is better than CHADS2 score in reducing ischemic stroke risk in patients with atrial fibrillation.
    Pieri A; Lopes TO; Gabbai AA
    Int J Stroke; 2011 Oct; 6(5):466. PubMed ID: 21951414
    [No Abstract]   [Full Text] [Related]  

  • 24. Stroke prevention in atrial fibrillation--pharmacologic strategies.
    Tiyyagura SR; Goldbarg SH; Mehta D
    Indian Heart J; 2007; 59(4):311-5. PubMed ID: 19126935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New anticoagulants for atrial fibrillation.
    De Caterina R; Kristensen SD; Renda G
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):446-53. PubMed ID: 19365276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation--a nationwide descriptive study in Taiwan.
    Lin LJ; Cheng MH; Lee CH; Wung DC; Cheng CL; Kao Yang YH
    Clin Ther; 2008 Sep; 30(9):1726-36. PubMed ID: 18840379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stroke prevention in atrial fibrillation.
    Piccini JP; Wallace TW; Patel MR; Becker RC
    Cardiovasc Drugs Ther; 2011 Dec; 25(6):561-70. PubMed ID: 21927837
    [No Abstract]   [Full Text] [Related]  

  • 29. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China.
    Hu D; Sun Y
    J Am Coll Cardiol; 2008 Sep; 52(10):865-8. PubMed ID: 18755352
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation.
    Mant JW
    Thromb Haemost; 2008 Jul; 100(1):14-5. PubMed ID: 18612531
    [No Abstract]   [Full Text] [Related]  

  • 32. Antithrombotic treatment for patients with paroxysmal atrial fibrillation and a low CHA2DS2-VASc score.
    Muscente F; De Caterina R
    J Cardiovasc Med (Hagerstown); 2017 Jan; 18 Suppl 1():e94-e99. PubMed ID: 27828831
    [No Abstract]   [Full Text] [Related]  

  • 33. [Modification of clinical profile of stroke in atrial fibrillation patients. Effect of antithrombotic treatment].
    García Escrivà A; López Hernández N; Hernández Lorido R; Oliver Navarrete C; Bustos S; Carneado Ruiz J; Gracia Fleta F; Moltó Jordá JM
    Rev Neurol; 2004 Mar 1-15; 38(5):401-5. PubMed ID: 15029514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stroke prevention versus bleeding risk in atrial fibrillation: a clinical dilemma.
    Hohnloser SH
    J Am Coll Cardiol; 2011 Jan; 57(2):181-3. PubMed ID: 21111556
    [No Abstract]   [Full Text] [Related]  

  • 35. Applying antithrombotic therapies to improve outcomes in patients with atrial fibrillation.
    Cannon C; Ezekowitz MD; Granger C
    Am J Cardiol; 2013 Aug; 112(4):S3. PubMed ID: 23910054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atrial fibrillation and stroke prevention.
    Kakar P; Lip GY
    Expert Rev Neurother; 2006 Oct; 6(10):1523-30. PubMed ID: 17078791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores.
    Pamukcu B; Lip GY; Lane DA
    Age Ageing; 2010 Sep; 39(5):533-5. PubMed ID: 20507847
    [No Abstract]   [Full Text] [Related]  

  • 38. [The BAFTA study].
    Di Pasquale G; Palareti G
    G Ital Cardiol (Rome); 2008 Nov; 9(11):735-9. PubMed ID: 19058663
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation.
    Rockson SG; Albers GW
    J Am Coll Cardiol; 2004 Mar; 43(6):929-35. PubMed ID: 15028346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors and stroke risk stratification for atrial fibrillation: limitations and new possibilities.
    Lip GY
    Am Heart J; 2008 Jul; 156(1):1-3. PubMed ID: 18585489
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.